Triggering an IgA response could increase COVID-19 vaccine efficacy
Two new studies suggest that SARS-CoV-2-specific IgA antibodies are more neutralising and therefore COVID-19 vaccines should encourage an IgA response.
List view / Grid view
Two new studies suggest that SARS-CoV-2-specific IgA antibodies are more neutralising and therefore COVID-19 vaccines should encourage an IgA response.
Study suggests reducing the expression of the methyl-CpG-binding domain 2 (MBD2) protein on macrophages could be a viable therapeutic strategy for lung fibrosis.
Researchers show that neutralising antibodies targeting the SARS-CoV-2 Spike protein have four distinct structures.
The new study shows how SARS-CoV-2 significantly remodels cellular processes in just an hour and identifies potential drug targets and therapeutics for COVID-19.
Researchers report that their LEAPS COV-19 peptides significantly improved survival in a murine model of COVID-19.
Recent reports suggest that both clinical and genetic risk factors may contribute to COVID-19 susceptibility and severity. Catherine Ball, Chief Scientific Officer of Ancestry®, discusses results of the company’s COVID-19 Research Study, designed to explore non-genetic and genetic associations with disease outcomes.
The novel probes, known as positive controls, could make it easier to validate rapid, point-of-care diagnostic tests for COVID-19 across the globe.
In this article Maria Bernabeu, Group Leader at EMBL, Barcelona, discusses why it is important to research and develop novel therapeutics for cerebral malaria and how her research group intends to develop a 3D blood-brain barrier model for this purpose.
A new study has identified the mechanisms through which the SARS-CoV-2 virus enters the brain and how the immune system responds once it does.
COVID-19 is known to infect the lungs; however, the dynamics of viral infection and replication are poorly understood. Alongside the Liverpool School of Tropical Medicine, Professor Lyle Armstrong and colleagues have been working to develop a human lung epithelium model of SARS-CoV-2 infection and replication. In this article, he describes…
This in-depth focus features articles on neuropilin-1, a potential new target for COVID-19 drug development, the creation of a lung model to enhance our understanding of SARS-CoV-2 infections and using proteomics to uncover the mechanisms behind COVID-19 symptom severity.
Researchers reveal how two genetic variations may contribute to COVID-19 disease severity and suggest the product of one, the CD209 antigen, may be a potential drug target.
Scientists have shown how SARS-CoV-2 induces changes in the architecture of host cells to drive replication and made their data available to all.
Rodent studies show that using antibodies with different targets and modes of action in combination is more effective at preventing and treating COVID-19.
Scientists developed a new culture technique for alveolospheres which they used to study how alveolar cells respond to SARS-CoV-2 infection.